Validation Data Gallery
Tested Applications
Recommended dilution
| Application | Dilution |
|---|---|
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Product Information
83241-1-PBS targets Glypican 2 as part of a matched antibody pair:
MP00156-2: 83241-1-PBS capture and 83241-2-PBS detection (validated in Cytometric bead array)
Unconjugated rabbit recombinant monoclonal antibody in PBS only (BSA and azide free) storage buffer at a concentration of 1 mg/mL, ready for conjugation. Created using Proteintech’s proprietary in-house recombinant technology. Recombinant production enables unrivalled batch-to-batch consistency, easy scale-up, and future security of supply.
This conjugation ready format makes antibodies ideal for use in many applications including: ELISAs, multiplex assays requiring matched pairs, mass cytometry, and multiplex imaging applications.Antibody use should be optimized by the end user for each application and assay.
| Tested Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Recombinant |
| Type | Antibody |
| Affinity | KD<1.00 x 10-12M KOff<1.00 x 10-6M KOn=1.07 x 105M |
| Immunogen | Glypican 2 fusion protein Ag4041 相同性解析による交差性が予測される生物種 |
| Full Name | glypican 2 |
| Calculated molecular weight | 579 aa, 63 kDa |
| Observed molecular weight | 62，70-100 kDa |
| GenBank accession number | BC027972 |
| Gene Symbol | GPC2 |
| Gene ID (NCBI) | 221914 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Protein A purification |
| UNIPROT ID | Q8N158 |
| Storage Buffer | PBS Only |
| Storage Conditions | Store at -80°C. |
Background Information
GPC2 (glypican 2), which is expected to be located in cell membrane and extracellular space. It is expressed in lymphoid tissue, skin and testis. The calculated molecular weight of the protein is 62 kDa. GPC2 is mainly active in growing nervous tissues and thyroid cancer tissues (PMID: 28616017). It participates in the growth and differentiation of neuronal axons. Increasing evidence has demonstrated the overexpression of GPC2 in neuroblastoma, a kind of childhood cancer. There is a discovery that GPC2 can be employed as a diagnostic, prognostic, and immunological predictor of generalized cancers. The study may broaden the train of thought toward application of GPC2 in immunotherapy (PMID: 35345673).